Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2021

View Archived Issues

Enrollment ongoing in phase I/II study of SPL-026

Intrommune Therapeutics initiates phase I study of INT-301 in adults with peanut allergy

Patient enrollment ongoing in phase I study of LBL-007 plus toripalimab in advanced melanoma

SARS-CoV-2 Nsp1 blockade restores antiviral host gene expression in infected cells

Targeting the LIGHT/LTbR pathway may be a strategy to eliminate leukemia stem cells

P2RX7 activator HEI-3090 shows promise for treating NSCLC

Initiation of phase II study of triple combination therapy for the treatment of chronic HBV

Navrogen describes fusion proteins targeting CA125

Osteoclast recycling reveals formation of new cell type that has key role in osteoporosis

Reduced GFAP levels tied to reduced disability worsening in SPMS under siponimod

Regeneron patents bispecific monoclonal antibody targeting TSLP and CD3

New cyclin-dependent kinase inhibitors identified at Chengdu Synowest Biotechnology

Mutant GTPase KRAS inhibitors discovered at Beijing Jacobio Pharmaceuticals

Lilly divulges new NNMT inhibitors

FDA issues EUA for Janssen COVID-19 Vaccine

Pilot trial investigates magnetic nanoparticles to treat locally advanced pancreatic cancer

Mitotech reports VISTA-2 data on SkQ1 for dry eye disease

New SARS-CoV-2 main protease inhibitors display antiviral activity in vivo

FDA grants accelerated approval to Pepaxto for relapsed or refractory melanoma

FDA approves Nulibry for molybdenum cofactor deficiency type A

Aslan reports promising clinical data on ASLAN-004 in atopic dermatitis

Oncorena cleared to begin phase I/II study in Sweden with orellanine for metastatic renal cancer

New phase I/II study evaluates BT-001 for solid tumors

Takeda initiates phase I/II study in Japan with NVX-CoV2373

Santhera reports phase Ib data on lonodelestat in cystic fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...